GBP15.16
2.73% yesterday
London, Mar 11, 05:44 pm CET
ISIN
GB00BN7SWP63
Symbol
GSK
Sector
Industry

GlaxoSmithKline Stock price

GBP15.16
+0.89 6.20% 1M
-1.02 6.31% 6M
+1.84 13.86% YTD
-0.93 5.80% 1Y
+1.29 9.27% 3Y
+2.89 23.60% 5Y
+5.74 60.93% 10Y
London, Closing price Tue, Mar 11 2025
-0.43 2.73%
ISIN
GB00BN7SWP63
Symbol
GSK
Sector
Industry

Key metrics

Market capitalization GBP61.79b
Enterprise Value GBP74.30b
P/E (TTM) P/E ratio 23.99
EV/FCF (TTM) EV/FCF 15.84
EV/Sales (TTM) EV/Sales 2.37
P/S ratio (TTM) P/S ratio 1.97
P/B ratio (TTM) P/B ratio 4.53
Dividend yield 4.02%
Last dividend (FY24) GBP0.61
Revenue growth (TTM) Revenue growth 3.46%
Revenue (TTM) Revenue GBP31.38b
EBIT (operating result TTM) EBIT GBP5.56b
Free Cash Flow (TTM) Free Cash Flow GBP4.69b
Cash position GBP3.89b
EPS (TTM) EPS GBP0.63
P/E forward 10.23
P/S forward 1.89
EV/Sales forward 2.27
Short interest 51.00%
Show more

Is GlaxoSmithKline a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,814 stocks worldwide.

GlaxoSmithKline Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a GlaxoSmithKline forecast:

7x Buy
30%
12x Hold
52%
4x Sell
17%

Analyst Opinions

23 Analysts have issued a GlaxoSmithKline forecast:

Buy
30%
Hold
52%
Sell
17%

Financial data from GlaxoSmithKline

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
31,376 31,376
3% 3%
100%
- Direct Costs 8,883 8,883
1% 1%
28%
22,493 22,493
5% 5%
72%
- Selling and Administrative Expenses 7,869 7,869
25% 25%
25%
- Research and Development Expense 6,078 6,078
15% 15%
19%
8,546 8,546
13% 13%
27%
- Depreciation and Amortization 2,985 2,985
5% 5%
10%
EBIT (Operating Income) EBIT 5,561 5,561
20% 20%
18%
Net Profit 2,575 2,575
48% 48%
8%

In millions GBP.

Don't miss a Thing! We will send you all news about GlaxoSmithKline directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GlaxoSmithKline Stock News

AD HOC NEWS
about one month ago
Der Pharmakonzern GSK GB00BN7SWP63 hat durch einen unerwartet starken Schlussspurt 2024 besser abgeschnitten als gedacht.
AD HOC NEWS
about one month ago
Der Pharmakonzern GSK GB00BN7SWP63 hat durch einen unerwartet starken Schlussspurt 2024 besser abgeschnitten als gedacht.

Company Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Head office United Kingdom
CEO Emma Walmsley
Employees 68,629
Founded 1999
Website www.gsk.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today